W. Michael Flanagan, Director of Atrium Therapeutics RNA, has filed 0 purchases and 19 sales on the open market. Over the past 12 months that comes to a net sale of $644.8K. The latest trade was on 02/27.

WF

WF

W. Michael Flanagan

Director

Company

Atrium Therapeutics RNA

First filing

23/01/24

Trades

54 trades

Buys / sales

0 / 19

12-month net buying

−$644.8K

Last trade

02/27

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
AB Avidity Biosciences	Open-market sale10b5-1 plan	01/21	01/23	6,534 sh2 trades	$72.45avg.	$473,388.3	−7.1%
AB Avidity Biosciences	Open-market sale10b5-1 plan	01/07	01/09	2,373 sh	$72.23	$171,401.79	−2.5%
AB Avidity Biosciences	Open-market sale10b5-1 plan	25/09/11	25/09/12	20,000 sh	$38.94	$778,800	−20.0%
AB Avidity Biosciences	Open-market sale10b5-1 plan	25/06/11	25/06/12	20,000 sh	$32.88	$657,600	−20.0%
AB Avidity Biosciences	Open-market sale10b5-1 plan	25/03/20	25/03/21	11,780 sh	$31.06	$365,886.8	−12.8%
AB Avidity Biosciences	Open-market sale10b5-1 plan	25/03/11	25/03/12	20,000 sh	$30.13	$602,600	−17.9%
AB Avidity Biosciences	Open-market sale10b5-1 plan	25/01/21	25/01/23	5,672 sh2 trades	$28.60avg.	$162,201.08	−5.8%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/12/18	24/12/19	12,742 sh	$32.66	$416,153.72	−14.9%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/12/11	24/12/13	24,000 sh	$35.77	$858,480	−21.9%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/10/01	24/10/03	62,500 sh	$47.62	$2,976,250	−42.3%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/09/23	24/09/23	25,000 sh2 trades	$43.95avg.	$1,098,696.83	−22.6%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/09/11	24/09/13	111,394 sh3 trades	$40.40avg.	$4,500,317.6	−64.7%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/06/18	24/06/20	10,106 sh	$39.13	$395,447.78	−16.6%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/01/22	24/01/23	4,129 sh	$10.13	$41,826.77	−10.3%